Effect of structural modification at the 4, 3′, and 2′ positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 55, Issue 3, 2007, Pages 193-198

  Gruber, Beata M ^a   Anuszewska, Elzbieta L ^a   Bubko, Irena ^a   Goździk, Aneta ^a   Fokt, Izabela ^b   Priebe, Waldemar ^b  

^a National Medicine Institute   (Poland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracyclines; Apoptosis; Cytotoxicity; Topoisomerase II poisons

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANNAMYCIN; ANTHRACYCLINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; UNCLASSIFIED DRUG; WP 903;

APOPTOSIS; ARTICLE; CELL TYPE; CORRELATION ANALYSIS; CYTOTOXICITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MELANOMA; PROTEIN INTERACTION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA;

EID: 34250786135     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-007-0018-6     Document Type: Article

References (27)

1. Anuszewska E. L., Gruber B. M. and Koziorowska J. H. (1997): Studies on adaptation to adriamycin in cells pretreated with hydrogen peroxide. Biochem. Pharmacol., 54, 597-603.
2. Arpino G., Ciocca D. R., Weiss H., Allred D. C., Daguerre P., Vargas-Roig L., Leuzzi M., Gago F., Elledge R. and Mohsi S. K. (2005): Predictive value of apoptosis, proliferation, HER-2, and topoisomerase II alpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat., 92, 69-75.
3. Capranico G., Supino R., Binaschi M., Capolongo L., Grandi M., Suarato A. and Zunino F. (1994): Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol.. 45, 908-915.
4. Cardoso F., Durbecq V., Larsimont D., Paesmans M., Leroy J. Y., Rouas G., Sotiriou C., Renard N., Richard V., Piccart M. J. and Di Leo A. (2004): Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int. J. Oncol., 24, 201-209.
5. De Boer R. A., van Veldhuisen D. J., van der Wijk J., Brouwer R. M., de Jonge N., Cole G. M. and Suurmeijer A. J. (2000): Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patient with chronic heart failure. J. Card. Fail., 6, 330-337.
6. Den Boer M. L., Pieters R. and Veerman A. J. (1998): Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia, 12, 1657-1670.
7. De Graff W. G., Myers L. S. Jr., Mitchell J. B. and Hahn S. M. (2003): Protection against adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid. Int. J. Oncol., 23, 159-163.
8. Di Leo A. and Isola J. (2003): Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin. Breast Cancer, 4, 179-186.
9. Durbecq V., Paesmans M., Cardoso F., Desmedt C., Di Leo A., Chan S., Friedrichs K., Pinter T., Van Belle S., Murray E., Bodrogi I., Walpole E., Lesperance B., Korec S. Crown J., Simmonds P., Perren T. J., Leroy J. Y., Rouas G., Sotiriou C., Piccart M. and Larsimont D. (2004): Topoisomerase II-alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol. Cancer Ther., 3, 1207-1214.
10. Gariboldi M. B., Ravizza R., Riganti L., Meschini S., Calcabrini A., Marra M., Arancia G., Dolfini E. and Montie E. (2003): Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int. J. Oncol., 22, 1057-1064.
11. Gewirtz D. A. (1999): A critical evaluation of the mechanism of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57, 727-741.
12. Grabowski D. R., Dubyak G. R., Rybicki L., Hidaka H. and Ganapathi R. (1998): Tumor cell resistance to topoisomerase II poisons. Role for intracellular free calcium in the sensitization by inhibitors of calcium-calmodulin-dependent enzymes. Biochem. Pharmacol., 56, 345-349.
13. Gruber B. M., Anuszewska E. L., Bubko I., Goździk A., Priebe W. and Fokt I. (2005): Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Res., 25, 2193-2198.
14. Gruber B. M., Anuszewska E. L. and Priebe W. (2004): The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. Folia Histochem. Cytobiol., 42, 127-130.
15. Gruber B. M., Anuszewska E. L., Roman I., Goździk A., Priebe W. and Fokt I. (2006): Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Pol. Pharm. Drug Res., 63,15-18.
16. Jarvinen T. A. and Liu E. T. (2003): HER-2/neu and topoisomerase II alpha in breast cancer. Breast Cancer Res. Treat., 78, 299-311.
17. Koshiyama M., Fujii H., Kinezaki M. and Yoshida M. (2001): Correlation between topo II alpha expression and chemosensitivity testing for topo II-targeting drugs in gynaecological carcinomas. Anticancer Res., 21, 905-910.
18. Lage H. and Dietel M. (2002): Multiple mechanisms confer different drug resistant phenotypes in pancreatic carcinoma cells. J. Cancer Res. Clin Oncol., 128, 349-357.
19. Li T.-K. and Liu L. F. (2001): Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol., 41, 53-77.
20. MacGrogan G., Rudolph P., Mascarel Id I., Mauriac L., Durand M., Avril A., Dilhuydy J. M., Robert J., Mathoulin-Pelissier S., Picot V., Floquet A., Sierankowski G. and Coindre J. M. (2003): DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer. Br. J. Cancer, 89, 666-671.
21. Martin-Richard M., Munoz M., Albanell J., Colomo L., Bellet M., Rey M. J., Tabernero J., Alonso C., Cardesa A., Gascon P. and Fernandez P. L. (2004): Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology, 66, 388-394.
22. Nowak R. and Tarasiuk J. (2004): The inhibition of apoptosis in cancer cells resistant to anticancer drugs (in Polish). Postȩpy Biochem., 50, 330-341.
23. Priebe W. (1995): Mechanism of action-governed design of anthracycline antibiotics: a "turn-off/ turn-on" approach. Curr. Pharm. Des., 1, 51-68.
24. Ramachandran Ch., Samy T. S., Huang X. L., Yuan Z. K. and Krishan A. (1993): Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochem. Pharmacol., 45, 1367-1371.
25. Sehested M. and Jensen P. B. (1996): Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-17) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 51, 879-886.
26. Trevino A. V., Woynarowska B. A., Herman T. S., Priebe W. and Woynarowski J. M. (2004): Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Mol. Cancer Ther., 3, 1403-1410.
27. Yamazaki K., Isobe H., Hanada T., Betsuyaku T., Hasegawa A., Hizawa N., Ogura S. and Kawakami Y. (1997): Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother. Pharmacol., 39, 192-198.